Your browser doesn't support javascript.
loading
Printing a cure: A tailored solution for localized drug delivery in liver cancer treatment.
Youssef, Souha H; Ganesan, Raja; Amirmostofian, Marzieh; Kim, Sangseo; Polara, Ruhi; Afinjuomo, Franklin; Song, Yunmei; Chereda, Bradley; Singhal, Nimit; Robinson, Nirmal; Garg, Sanjay.
Afiliação
  • Youssef SH; Centre for Pharmaceutical Innovation (CPI), University of South Australia, Adelaide, SA, Australia.
  • Ganesan R; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Amirmostofian M; Clinical & Health Sciences, University of South Australia, Adelaide, SA, Australia.
  • Kim S; Centre for Pharmaceutical Innovation (CPI), University of South Australia, Adelaide, SA, Australia.
  • Polara R; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Afinjuomo F; Centre for Pharmaceutical Innovation (CPI), University of South Australia, Adelaide, SA, Australia.
  • Song Y; Centre for Pharmaceutical Innovation (CPI), University of South Australia, Adelaide, SA, Australia.
  • Chereda B; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.
  • Singhal N; Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia; Dept of Medicine, University of Adelaide, Adelaide, SA, Australia.
  • Robinson N; Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia; Discipline of Medicine and the Faculty of Health Science, University of Adelaide, Adelaide, SA, Australia.
  • Garg S; Centre for Pharmaceutical Innovation (CPI), University of South Australia, Adelaide, SA, Australia. Electronic address: Sanjay.garg@unisa.edu.au.
Int J Pharm ; 651: 123790, 2024 Feb 15.
Article em En | MEDLINE | ID: mdl-38190951
ABSTRACT
Adjuvant chemotherapy is highly recommended for liver cancer to enhance survival rates due to its tendency to recur frequently. Localized drug-eluting implants have gained traction as an alternative to overcome the limitations of systemic chemotherapy. This work describes the development of biodegradable 3D printed (3DP) bilayer films loaded with 5-fluorouracil (5FU) and cisplatin (Cis) with different infill percentages where the 5FU layers were 40%, 30%, and 30% and Cis layers were 10%, 15%, and 10% for films A, B, and C, respectively. The relevant characterization tests were performed, and the drug content of films was 0.68, 0.50, and 0.50 mg of 5FU and 0.39, 0.80, and 0.34 mg of Cis for films A, B, and C, respectively. Cis release was affected by the alterations to the film design, where films A, B, and C showed complete release at 12, 14, and 23 days, respectively. However, 5FU was released over 24 h for all films. The films were stable for up to two weeks after storage at 25 °C/65% relative humidity and four weeks at 4 °C where drug content, tensile strength, FTIR, and thermal analysis results demonstrated negligible alterations. The cytotoxicity of the films was assessed by MTS assays using HepG2 cell lines demonstrating up to 81% reduction in cell viability compared to blank films. Moreover, apoptosis was confirmed by Western Blots and the determination of mitochondrial cell potential, highlighting the potential of these films as a promising approach in adjuvant chemotherapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Neoplasias Hepáticas Limite: Humans Idioma: En Revista: Int J Pharm Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Neoplasias Hepáticas Limite: Humans Idioma: En Revista: Int J Pharm Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália